NMTR - 9 Meters Biopharma enters collaboration deal for bowel syndrome treatment development

9 Meters Biopharma (NMTR) will enter into a collaboration with the Duke Clinical Research Institute to support the clinical development of 9 Meters' candidate NM-002, a proprietary long-acting GLP-1 agonist, currently in Phase 2 development for short bowel syndrome ((SBS)).9 Meters' clinical trial is a Phase 2, double-blind, multicenter, placebo-controlled, parallel group study of the safety, efficacy and tolerability of NM-002 in adult patients with short bowel syndrome, with total stool output will serve as the primary endpoint in this study.Topline data is expected in the fourth quarter of 2021, with a Phase 3 expected to begin in the same quarter.Shares of the company up nearly 2% premarket.

For further details see:

9 Meters Biopharma enters collaboration deal for bowel syndrome treatment development